Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. by Lumpkin, Ryan J et al.
UC San Diego
UC San Diego Previously Published Works
Title
Site-specific identification and quantitation of endogenous SUMO modifications under 
native conditions.
Permalink
https://escholarship.org/uc/item/2m30p47q
Journal
Nature communications, 8(1)
ISSN
2041-1723
Authors
Lumpkin, Ryan J
Gu, Hongbo
Zhu, Yiying
et al.
Publication Date
2017-10-27
DOI
10.1038/s41467-017-01271-3
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ARTICLE
Site-specific identification and quantitation of
endogenous SUMO modifications under native
conditions
Ryan J. Lumpkin1, Hongbo Gu2, Yiying Zhu2, Marilyn Leonard3, Alla S. Ahmad 1, Karl R. Clauser4,
Jesse G. Meyer 1, Eric J. Bennett 3 & Elizabeth A. Komives1
Small ubiquitin-like modifier (SUMO) modification regulates numerous cellular processes.
Unlike ubiquitin, detection of endogenous SUMOylated proteins is limited by the lack of
naturally occurring protease sites in the C-terminal tail of SUMO proteins. Proteome-wide
detection of SUMOylation sites on target proteins typically requires ectopic expression of
mutant SUMOs with introduced tryptic sites. Here, we report a method for proteome-wide,
site-level detection of endogenous SUMOylation that uses α-lytic protease, WaLP. WaLP
digestion of SUMOylated proteins generates peptides containing SUMO-remnant diglycyl-
lysine (KGG) at the site of SUMO modification. Using previously developed immuno-affinity
isolation of KGG-containing peptides followed by mass spectrometry, we identified 1209
unique endogenous SUMO modification sites. We also demonstrate the impact of protea-
some inhibition on ubiquitin and SUMO-modified proteomes using parallel quantitation of
ubiquitylated and SUMOylated peptides. This methodological advancement enables deter-
mination of endogenous SUMOylated proteins under completely native conditions.
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The family of small ubiquitin-like modifier (SUMO) pro-teins in humans includes four distinct genes with threetypes of members: SUMO1, SUMO2/3 (which differ by
only three residues), and SUMO4. SUMO proteins regulate the
function of various proteins by reversible covalent isopeptide
bond attachment between the C terminus of SUMO and a free ε-
amine group typically on lysine residues within target proteins1,
similar to ubiquitin (Ub). Ub conjugation mainly targets proteins
for degradation by the proteasome, but has also been implicated
in DNA repair, receptor signaling, and cell communication2. The
function of SUMO conjugation on target proteins is similarly
diverse with SUMOylation catalyzing alteration of protein activity
for targets involved in gene expression, DNA repair,
nuclear import, heat shock, cell motility, and lipid metabolism1,3.
SUMO targets are generally low-abundance proteins, and the
amount of the modification at steady state is also low4. Given its
importance in numerous cellular functions, several groups have
developed proteomic methods for analysis of SUMOylated
proteins.
Three general approaches have been previously utilized to
isolate and identify the SUMOylated proteome5. Ectopic expres-
sion of epitope-tagged SUMO followed by standard isolation
techniques and mass spectrometry has been widely used in a
variety of organisms6–10. These approaches have yielded various
maps of SUMO-interacting proteins but few sites of SUMOyla-
tion are identified by this approach and the extent to which
exogenous expression of modified SUMOs alters substrate tar-
geting is unknown. Immuno-affinity approaches utilizing anti-
bodies that recognize endogenous SUMO2/3 or SUMO1 have
been used to identify SUMO-interacting proteins under endo-
genous conditions4. However, as with the epitope-tagging
approach, few actual sites of SUMO modification were identi-
fied using this method. Therefore, methods that allow proteome-
level identification of endogenous SUMOylation sites are needed.
A robust proteomic method has been developed to measure
thousands of endogenous ubiquitylation sites11. The method
takes advantage of the C-terminal sequence of Ub (RGG)
(Fig. 1a). When cleaved with trypsin, ubiquitylated substrate
proteins will generate peptides containing a Ub-remnant diglycyl-
lysine (KGG) that can be enriched using specific antibodies and
identified by tandem mass spectrometry (Fig. 1b)12–14. Instead of
the trypsin-friendly arginine residue preceding the C-terminal
diGlycine sequence observed in the processed Ub sequence,
mature human SUMO paralogs have a threonine preceding the
C-terminal diGlycine sequence and no other tryptic cleavage sites
near the C terminus (Fig. 1a). To overcome this problem, various
schemes that introduce mutations within the C terminus of
SUMO to render it more amenable to trypsin-based cleavage and
identification by mass spectrometry have been developed for
global profiling of SUMO attachment sites15,16. Several groups
have reported global profiling approaches in which mutant
SUMOs with various affinity tags and protease recognition sites
were introduced into cells. For example, Hendriks et al. intro-
duced a lysine-deficient SUMO-3 with a C-terminal trypsin
cleavage site, His10–SUMO-3 K0 Q87R17,18. The SUMOylated
proteins were enriched by immobilized metal affinity chromato-
graphy (IMAC) and digested with Lys-C. Peptides modified with
SUMO were then purified again with IMAC and finally digested
with trypsin to generate a five amino acid C-terminal SUMO-
remnant modification. This group has compiled all available data
resulting in 7327 SUMOylation sites in 3617 proteins17. Other
groups have used similar engineering approaches to express
mutant SUMOs and identify up to 1000 unique SUMOylation
sites upon induction of cell stress15,16,18–20. While these methods
have proved effective in mapping SUMOylation sites, they all
require exogenous expression of mutant version of SUMO, which
preclude analysis of SUMO-modification sites in native settings
or from human tissues. Currently, no method exists for identi-
fying endogenous SUMO sites on a global proteome scale without
introduction of mutant SUMO.
We recently described the application of wild-type α-lytic
protease (WaLP) to proteome digestion for shotgun pro-
teomics21. Although relatively relaxed specificity was observed,
WaLP prefers to cleave after threonine residues and rarely cleaved
after arginine21. In addition, WaLP generates peptides of the
same average length as trypsin despite its more relaxed substrate
specificity21. We show here that WaLP cleaves at the C-terminal
TGG sequence (all SUMO paralogs) leaving a SUMO-remnant
KGG at the position of SUMO attachment in target proteins.
The resulting KGG-containing peptides can then be identified
using methods already developed for profiling the Ub-modified
proteome as described above (Fig. 1c). The method allows iden-
tification of SUMO attachment sites under completely native
conditions using the Ub-profiling workflow by simply substitut-
ing WaLP for trypsin. The same sample can be subjected to
analysis of both the Ub- and SUMO-modified proteomes simply
by digesting the sample with either trypsin or WaLP, respectively.
We demonstrate the effectiveness of this parallel identification of
ubiquitylation and SUMOylation sites in cells treated with
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Fig. 1 A strategy for mapping endogenous SUMO-modification sites.
a C-terminal sequence alignment of processed human SUMO1-4 and
ubiquitin. The proximal amino acid to the diGlycine C-terminal residues is
indicated in red. b Schematic depicting the Ub site mapping strategy.
Proteins modified by ubiquitin are digested with trypsin leaving a diGlycine
attached to the ε-amine of the lysine where ubiquitin was attached. An
antibody specific for KGG-peptides is used to enrich peptides from
ubiquitylated sites that are then identified by mass spectrometry. c The
same as b but WaLP digestion is used to generate the KGG-peptides from
SUMO attachment sites
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proteasome inhibitors. We provide the description a unique
method of identifying proteins containing individual lysine resi-
dues that are modified by both SUMO and Ub from the same
sample. This method can be simply applied to any sample,
including human tissues samples, to identify endogenous
SUMOylation sites.
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Fig. 2 Summary of SUMOylation site identifications from this study and comparison with previous studies. a Venn diagram showing overlap between the
1209 SUMO sites identified in this study from both Hela and HCT116 cell lines (blue) and all SUMO modifications from either Hendriks et al. (red) or
Phosphosite Plus (yellow). b Identified spectrum of a novel SUMO modification site identified in DNA-PK that would have resulted in a 57-amino-acid
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Results
SUMOylation site profiling by WaLP digestion. Previous stu-
dies demonstrated the utility of WaLP digestion in shotgun
proteomics platforms21. Our observation that threonine was
among the preferred amino acids in the P1 position for WaLP
digestion21 led us to hypothesize that digestion of SUMOylated
proteins with WaLP, which should cleave after the threonine in
the SUMO C-terminal sequence, TGG, would generate a SUMO-
remnant diglycyl-lysine (KGG) at SUMOylation sites (Fig. 1a).
The same workflow used for Ub-remnant profiling could then be
used to globally profile SUMO attachment sites (Fig. 1b, c).
Although WaLP can simply be substituted for trypsin during
sample preparation, identification of non-tryptic peptides pro-
duced from WaLP digestion is challenging because search engines
score on the basis of b and y ion series that are expected from
tryptic peptides with a C-terminal positive charge. We previously
demonstrated that identification of peptides arising from WaLP
digestion benefits from electron transfer dissociation (ETD)22,
whereas higher-energy collisional dissociation generates internal
ions that can complicate peptide spectral matching21. WaLP
cleaves after at least four different amino acids requiring the use
of “no enzyme” specificity in database searches, which is chal-
lenging for many publicly available search algorithms. To facil-
itate mapping of SUMOylation sites using WaLP digestion, we
used the MS-GF+ search engine whose scoring function can be
trained using identifications from an initial search23,24.
Identification of novel SUMOylation sites using WaLP. As an
initial test of the method, we digested lysates generated from
human cell lines with WaLP and enriched for KGG-containing
peptides using established protocols for Ub-modified peptide
enrichment14. Subsequent analysis by mass spectrometry and
database searching using MS-GF+ resulted in the identification of
2051 unique KGG-containing peptides, which were confidently
localized (PTMprophet score >0.9) to 1209 unique sites (Sup-
plementary Data 1). Comparison of the SUMOylation sites
identified using our WaLP digestion approach with the
SUMOylation sites amalgamated by Hendriks et al.17 revealed an
overlap of only 30% (Fig. 2a). When compared to previously
reported SUMOylation sites from Hendriks et al. (7710 sites)17,
Phosphosite Plus (780 sites)25, and Uniprot (1863 sites)26, 826
were novel. Peptides containing SUMO remnants from WaLP
digestion may correspond to sequences that are not covered by
tryptic digestion due to the abundance or lack of nearby tryptic
cleavage sites21. We found several examples of such cases. For
example, we identified a novel SUMOylation site in DNA-PK
(PRKDC, P78527), which would have been in a tryptic peptide of
length 57 (Fig. 2b), and another in Sp100 (P23497), which would
have been a tryptic peptide of only six amino acids (Fig. 2c).
Multiple SUMOylation sites were found in over 60% of the
proteins identified, with 5% having more than six SUMOylation
sites. The SUMOylation sites identified in this study correspond
to the expected motifs as described by others. We found that 31%
of the SUMO attachments occurred at the “forward” sequence
motif (ΨKX[E|D]) (Supplementary Fig. 1a), 9% corresponded to
the “inverted” motif ([E|D]XK) (Supplementary Fig. 1b), and 60%
did not correspond to either consensus but these sites were
somewhat enriched in acidic residues (Supplementary Fig. 1c).
Gene ontology term enrichment was performed to functionally
annotate the SUMO-modified proteins. As reported previously,
SUMOylation sites were primarily found in nuclear proteins and
SUMOylated proteins were enriched for proteins involved in
chromatin biology, RNA metabolism, and transcription (Sup-
plementary Fig. 2).
It is possible that the same lysine within an individual protein
can be either modified by Ub or SUMO and that SUMOylation
may antagonize ubiquitylation27–29. In fact, 30% of the sites
identified in this study were either previously reported to be
ubiquitylated in the Phosphosite Plus database or were found in
our experiments to be ubiquitylated. This overlap is similar to
that previously reported by Hendriks et al.18.
Validation of SUMOylation sites using in vitro deSUMOyla-
tion. Our previous studies on WaLP digestion specificity indi-
cated that WaLP rarely cut after arginine residues (Fig. 1b) leads
to the possibility of using WaLP to generate diGlycine-remnant
peptides from SUMO-modified proteins and not Ub-modified
proteins. However, when using WaLP to isolate and identify
SUMOylated peptides in this study, we occasionally identified
peptides whose MS/MS spectra matched best to peptides that
resulted from cleavage after arginine either on the N or C ter-
minus. These peptides were rare, with percentages varying from
3–8%, which we attribute at least partly to our inability to com-
pletely remove the trypsin used to detach cells during scale-up.
Trypsin was avoided in cell harvesting, scraping was used instead.
Even still, the fact that the P1 Arg was usually present in a
sequence that had multiple positively charged residues in a row
led us to question whether WaLP digestion could occasionally
result in the generation of a KGG-peptide from a ubiquitylated
protein. To evaluate this possibility and to validate our approach,
native cell lysates were either untreated or treated with recom-
binant deSUMOylating enzymes, SENP1 and SENP2, prior to
digestion with either trypsin or WaLP. Western blot analysis
revealed that in vitro treatment with SENP1/2 resulted in a robust
reduction of SUMO1- and SUMO2/3-modified proteins while
leaving ubiquitylated proteins unaltered (Fig. 3a). Digestion of
SENP1/2-treated lysates with trypsin or WaLP and subsequent
analysis by mass spectrometry revealed a dramatic reduction in
the abundance of KGG-modified peptides from WaLP-digested
samples compared to untreated samples (Fig. 3b). Importantly,
the abundance of KGG-peptides resulting from trypsin cleavage,
which would arise from ubiquitylated substrates, was unaltered by
SENP1/2 treatment (Fig. 3b). The observation that 88% of sites
identified after WaLP digestion were decreased at least twofold
upon SENP1/2 treatment validated our approach. Conversely,
treatment of lysates with a promiscuous deubiquitylating enzyme,
Usp2cc, would result in a specific decrease in the amount of a
KGG-peptide from a ubiquitylated site without altering
SUMOylated peptides. Consistent with our prediction, less than
2% of KGG-peptides generated from WaLP-digested cells
decreased upon Usp2cc treatment (a similar percentage to the
FDR), whereas 97% of the KGG-containing peptides generated
from trypsin digestion decreased after Usp2cc treatment (Fig. 3c).
Taken together, we conclude that WaLP digestion and subsequent
immuno-affinity enrichment of KGG-modified peptides specifi-
cally identifies endogenous SUMOylated peptides.
Parallel Ub and SUMO site identification. A unique feature of
our method is the ability to identify ubiquitylation and
SUMOylation sites in parallel from the same cell or tissue lysate.
The lysate can be simply split in half, with one half digested with
WaLP and the other half digested with trypsin (Fig. 1c, d). The
subsequent immuno-affinity enrichment steps are identical,
although mass spectrometry and data processing were optimized
for tryptic peptides for Ub and non-tryptic peptides for SUMO.
As is already well established, SUMOylation is a lower abundance
modification than ubiquitylation, and indeed, we identified 6472
Ub sites in the same samples in which 1209 SUMO sites were
identified. Qualitative comparisons of the data revealed all
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possible types of dual modification scenarios. We found 2713
proteins that were ubiquitylated, 768 proteins that were
SUMOylated, and 407 proteins that had both SUMO and Ub.
Some had a large number of ubiquitylated lysines and few
SUMOylated lysines while others had larger numbers of SUMO-
modified lysines and few ubiquitylated sites. Those for which we
observed both modifications mostly carried those modifications
on different residues. We observed 243 lysines that were found to
be Ub modified in the trypsin-digested samples and SUMO
modified in the WaLP-digested samples. These results indicate
that our method can identify proteins that are modified by both
SUMO and Ub on the same lysine residues in the same sample.
Parallel quantification of Ub and SUMO sites. Previous studies
indicated that SUMO modification could be stimulated by cell
stresses such as heat shock and proteasome inhibition30,31. Using
SILAC-based quantitative proteomics, and our method allows for
the parallel capture, identification, and quantification of SUMO-
and Ub-modified proteins in response to various cell perturba-
tions. As it is well established that proteasome inhibition results
in global alteration of the Ub-modified proteome, we evaluated
the dynamic response of both the Ub- and SUMO-modified
proteome to proteasome inhibition. Metabolically labeled cells
were treated with MG132 and mixed with unlabeled cells prior to
cell lysis. Again, the cell lysates were split and half was digested
with trypsin for Ub analysis and the other half was digested with
WaLP for SUMO analysis. We identified and quantified 330
unique SUMOylated sites and 2621 unique ubiquitylation sites
from biological replicate samples. The results for both experi-
ments were normally distributed (Fig. 4) and the results from the
Ub analysis were comparable to previously published data in
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Fig. 3 Identification and quantitation of SUMO and Ub modification sites upon in vitro deSUMOylation in Hela cell extracts. a Extracts were either
untreated or treated with varying amounts of SENP1 and SENP2 enzymes or Usp2cc and then analyzed by SDS-PAGE and blotted for SUMO1 or SUMO2/3
or ubiquitin. b Bar graph showing results from quantitation of KGG-peptides after treatment with SENP1/2, illustrating the reduction of KGG sites observed
after WaLP digestion. Green bars indicate SUMO modification sites identified and quantified upon WaLP digestion (left, y axis) and blue bars indicate Ub
modification sites identified and quantified upon trypsin digestion (right, y axis). c Bar graph showing results from quantitation of KGG-peptides after
treatment with Usp2cc, illustrating the retention of KGG sites observed after WaLP digestion. Colors are the same as in b
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which proteasome inhibitors were utilized14,32. For the SUMO
analysis, 30 sites increased in abundance by at least twofold and
72 sites decreased in abundance by at least twofold upon MG132
treatment18. Changes in modification abundance are not likely
due to changes in protein levels as protein levels were not found
to change significantly during a 4-h MG132 treatment14. We
observed 103 proteins for which both SUMOylation and ubi-
quitylation could be quantified. These proteins had a total of 591
modified lysines. Of the total 591 modified lysines, 53 were found
to be both SUMOylated and ubiquitylated.
The proteins with the most abundant sites that were both
SUMOylated and ubiquitylated were SUMO and Ub themselves,
so we analyzed these to see if any sites were reciprocally regulated.
It is important to note that we observed multiple modified
peptides with more than one SUMO modification on SUMO
proteins only in the WaLP digest. This indicates the presence of
SUMO molecules that are simultaneously SUMOylated at
different lysine residues and may have a branched-chain
architecture. Interestingly, SUMO-modified ubiquitin was only
observed on single lysine residues, suggesting that multiply
SUMO-modified ubiquitin is a rare or nonexistent event.
Conversely, peptides with more than one Ub modification on
ubiquitin were observed only in the trypsin digest. These results
are consistent with the presence of poly-SUMO (detected by
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WaLP) and poly-Ub (detected by trypsin) but only mono-
modifications of the opposite protein. We quantified ubiquityla-
tion and SUMOylation of three lysine residues in SUMO2/3 upon
MG132 treatment (Fig. 5a). Neither ubiquitylation nor SUMOy-
lation of lysines 33 or 45 in SUMO2/3 were dramatically altered
upon proteasome inhibition. However, ubiquitylation of lysine 11
on SUMO2/3 increased, whereas SUMOylation on this site
decreased upon MG132 treatment (Fig. 5a). Cross-modification
of SUMO2/3 by ubiquitin has been previously observed, and
consistent with these results, ubiquitylation of SUMO2/3 on
lysine 11 increases upon proteasome inhibition31.
For ubiquitin, we were able to quantify Ub and SUMO
modification of lysines 27, 29, 33, 48, and 63 (Fig. 5b), Both
SUMOylation and ubiquitylation of ubiquitin responded similarly
to MG132 treatment (Fig. 5b). Both SUMO and Ub modification
of lysines 48, 29, and 33 increased in abundance upon MG132
treatment. Conversely, both SUMO and Ub modifications on
lysine 63 of Ub decreased in abundance in the MG132-treated
cells. Similarly, we observed cross-modification of another
ubiquitin-like (Ubl) protein, Nedd8. Lysines 11 and 48 on Nedd8
were observed to be modified by both Ub and SUMO and the
extent of modification was largely unperturbed by proteasome
inhibition (Fig. 5c). Trypsin digestion followed by KGG immuno-
affinity enrichment cannot distinguish between ubiquitylation or
neddylation due to the presence of an arginine preceding the C-
terminal diGlycine in both Ub and Nedd8. As such, it is possible
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Fig. 5 Log2 SILAC ratios (heavy-MG132-treated:light-untreated HCT116 cells) for quantified ubiquitin (red) and SUMO (blue)-modified peptides observed
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that Nedd8 may be poly-neddylated at these sites rather than
ubiquitylated. Consistent with this observation, DCN1 was
observed to be diGlycine-modified at a lysine residue previously
characterized to be a neddylation site and this same lysine residue
was SUMOylated (Fig. 5c). Interestingly, the abundance of both
SUMOylated and neddylated DCN1 decreased upon proteasome
inhibition. These observations suggest that cross-modification of
Ubl proteins is prevalent and may possibly be antagonistic
modifications.
Separate from the highly abundant Ubl proteins, we observed a
few examples of proteins that were modified by both SUMO and
Ub on the same lysine residue with differential responses to
proteasome inhibition. For example, we quantified two SUMOy-
lation and nine ubiquitylation sites on annexin A1 (Fig. 5d). We
observed SUMOylation at Lys 147, which has not been previously
reported, and at Lys 312, a known SUMOylation and ubiquityla-
tion site18. This C-terminal lysine appears to experience
reciprocal regulation by MG132 as the abundance of the
SUMO-modified form was significantly decreased, whereas the
ubiquitylation was significantly increased (Fig. 5d). Further, lysine
26 in caveolin-1 and lysine 140 in the large ribosomal protein 15
were modified by both Ub and SUMO and these modifications
displayed divergent abundance alterations upon proteasome
inhibition (Fig. 5e, f). These results indicate that reciprocal
modification by SUMO and Ub on the same lysine within a target
protein may be a relatively rare event, but that it clearly does
occur at some sites in the proteome and that these modification
events may impart differential functional outputs for the substrate
proteins. These results also point to a unique strength of our
method in that it allows for parallel mapping of regulated
ubiquitylation and SUMOylation sites from a single sample.
Identification of SUMOylation in tissue samples. One advan-
tage of our method is that it allows for the identification of
endogenous SUMOylation sites from native tissues without exo-
genous SUMO protein expression. To establish this application of
our method, we processed murine tissue from brain, heart,
muscle, and liver to establish this application of our method, we
processed murine SUMOylated proteins in vivo. We identified
144 unique SUMOylation sites across the four tissues (Supple-
mentary Data 2). Overall, muscle and liver had the most similar
SUMOylated proteins, sharing ~70% of the total sites observed in
those tissues, whereas brain had the most unique SUMOylated
proteins that were not found in any other tissue type. We iden-
tified the well-characterized SUMOylated protein RANGAP1 in
all tissues validating our approach. Interestingly, we again iden-
tified ubiquitin as a SUMO-modified protein with lysines 48 and
63 serving as the SUMOylation sites in all tissues. This result
suggests that ubiquitin is SUMOylated at critical lysine residues
in vivo and validates that our approach can be successfully
applied toward the identification of endogenous SUMOylation
sites in tissues.
Discussion
We set out to develop a method for global profiling of native
SUMOylation events by taking advantage of the propensity of
WaLP for cleavage after threonine. By simply substituting WaLP
for trypsin, it was possible to immunopurify and identify a large
number of KGG-containing peptides corresponding to SUMO
remnants. A large number of the identified sites corresponded to
as-yet-unreported SUMOylation events. Several reasons could
explain the large number of new sites identified. First, as we
reported previously, the orthogonal specificity of WaLP allows
cleavage of proteins at sites that may not be accessible to tryp-
sin21. Second, although previous studies attempted to achieve
minimal expression of their mutant SUMO construct, it is pos-
sible that slight overexpression of SUMO or the presence of
mutant sequences could cause unnatural SUMO attachment.
Third, our method does not differentiate between SUMO1–4,
whereas Hendriks et al. examined only SUMOylation sites uti-
lizing SUMO-3 attachment18. One caveat is that WaLP also
cleaves after Leu and to some extent Ile, so the method does not
distinguish between SUMOylated, Fat10ylated, or Fub1ylated
proteins. However, the observation that 88% of WaLP diGly
proteins were reduced upon SENP1/2 treatment argues that the
vast majority of observed KGG sites arise from SUMOylation.
Additionally, analysis of the observed sites recapitulates previous
reports of the expected motifs of SUMOylation and GO term
enrichment19.
A powerful advantage of our method is that it allows for
simultaneous determination of ubiquitylation and SUMOylation
in the same sample. The same population of cells or tissue can be
subjected to analysis of both Ub attachment and SUMO attach-
ment simply by splitting the sample in two and digesting half with
trypsin and the other half with WaLP. The samples can then be
processed in parallel to immunopurify peptides for the presence
of the KGG modification, and sequence by mass spectrometry.
For the mass spectrometry, it is best to use optimized ionization
approaches and data analysis tailored to the non-tryptic WaLP
peptides. Although the commercial antibody used in this study
was developed for enrichment of KGG-peptides from Ub mod-
ification, it appears to also efficiently immunopurify KGG-
peptides from SUMOmodification. Finally, the method allows for
identification of SUMOylated proteins under native conditions
including from tissue samples.
Methods
WaLP. WaLp was expressed from Lysobacter enzymogenesis type 495 (ATCC)
using Bachovichin’s media supplemented with MEM vitamins and 60 g l−1sucrose.
L. enz. was grown at 30 °C with shaking at 100 rpm for 3 days. WaLP was purified
from the culture supernatant as described previously33. Briefly, the protease was
captured from the supernatant by batch binding on SP-sepharose, which is washed
extensively and then eluted with high pH glycine buffer. After buffer exchange to
pH 7.2, the enzyme was loaded onto an FPLC monoS 10/10 column and eluted
with a gradient of 10 mM NaHPO4, pH 7.2 to the same buffer containing 250 mM
sodium acetate over 1 h.
SENP1 and SENP2 deSUMOylation. To verify the in vitro deSUMOylation and
deubiquitylation assay, untreated HCT116 cells were harvested and lysed with
denaturing lysis buffer (8M urea, 150 mM NaCl, 50 mM Tris pH 7.8, 1 mM
sodium orthovanadate, 1 mM NaF, 1 mM sodium 2-glycerophosphate, protease
inhibitor tablet (Roche), 5 mM N-Ethylmaleimide (NEM, made fresh in methanol).
Lysates were sonicated and centrifuged at 20,000×g for 10 min at 4 °C to remove
insoluble material. Lysates were then diluted to 1M urea using cold 50 mM Tris pH
7.8. Dithiothreitol (DTT) was then added to the lysates at a final concentration of
15 mM. Lysates were then untreated or treated with a mixture of SENP1/2 (Life
Sensors) or Usp2cc (Enzo Life Sciences) for 4 h at 25 °C. For SENP1/2 treatment,
we initially used 2 Umg−1, 4 Umg−1, and 6 Umg−1 concentrations for the vali-
dation experiments and 1 μg mg−1 (total protein) for Usp2cc. Reactions were
quenched by addition of SDS sample buffer and samples were then processed for
SDS-PAGE and immunoblotting. The antibodies used for immunoblotting were
against ubiquitin (MAB1510, EMD Millipore, 1:1000 dilution), SUMO1 (4930, Cell
Signaling Technologies, 1:1000 dilution), and SUMO2/3 (4971, Cell Signaling
Technologies, 1:1000 dilution).
Hela cells were cultured in MEM media with 10% fetal bovine serum and 1%
penicillin/streptomycin at 37 °C with 5% CO2. Heat shock was performed at 43 °C
for 1 h, then Hela cells were washed with cold PBS, and harvested with 8M urea
lysis buffer (50 mM Tris pH 8.0, 8 M urea, 1 mM vanadate, 2.5 mM sodium
pyrophosphate, 1 mM beta-glycerol-phosphate). Extracts were sonicated and
centrifuged at 20,000×g for 15 min to remove insoluble material. Protein
concentrations were measured by Bradford Assay.
The cell lysate was diluted fourfold by addition of 50 mM Tris buffer pH 8.0 to a
final urea concentration of 2 M, and a DTT stock solution was added to a final
concentration of 4.5 mM. Equal amounts of lysates were reduced with 4.5 mM
DTT at 56 °C for 30 min and alkylated by adding iodoacetamide to 9 mM for
15 min in the dark. Additional DTT was added to lysate to concentration of
4.5 mM. In vitro deSUMOylation reaction was performed by adding specific
SUMO protease 1 (SENP1) and SUMO protease 2 (SENP2) (Life Sensors, Malvern,
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PA) at 10 units per milligram of lysate protein and incubating with lysate for
overnight at room temperature. In vitro de-ubiquitination reaction was performed
by adding USP2cc (Enzo Life Sciences) at an enzyme-to-substrate ratio of 1:500
and incubating at RT for 4 h. Untreated control lysate samples were also prepared.
Efficiency of SUMOylation cleavage by SUMO proteases and ubiquitin cleavage by
USP2cc was verified by western blots using primary antibodies for SUMO1 (4930),
SUMO2/3 (4971), and ubiquitin (3933) from Cell Signaling Technology. The
lysates were digested by WaLP or trypsin, an enzyme-to-substrate ratio of 1:100 at
37 °C overnight with slow rotation. Digestion was stopped by adding 20% TFA
solution to final TFA concentration of 1%. Peptides were then subject to C18
cleaning by Sep-Pak cartridges (Waters Corp.) and lyophilized.
Enrichment of KGG-containing peptides. For each 5–7 mg peptide sample, 10 µl
of UbiScan beads (20 µl of slurry, Cell Signaling Technology) was used to immu-
nopurify the KGG-containing peptides according to the CST protocols. First, the
digests were resuspended in 0.35 ml 2× IAP buffer (100 mM MOPS, 20 mM
Na2HPO4, 100 mM NaCl, pH 7.5), the pH was adjusted to 7.5, and cleared by
centrifugation at 10,000×g for 10 min at 4 °C. Then the digests were pre-cleared by
rocking with protein A resin for 1 h at 4 °C. Next, the KGG-peptides were
immunopurified from the digests by incubation with the UbiScan beads for 2 h
with rocking at 4 °C. After isolating the beads by centrifugation at 1000×g for
1 min, the beads were washed two times with 1× IAP buffer, then four times with
HPLC-grade water. The peptides were eluted in two steps. The beads were incu-
bated at room temperature with 55 µl of 0.15% TFA for 10 min, centrifuged at
3500×g for 1 min, and the supernatant carefully saved. Then the beads were
incubated for an additional 10 min with followed by 45 µl of 0.15% TFA for 10 min,
centrifuged at 3500×g for 1 min, and the supernatant was combined with the first
elution. The samples were analyzed by nLC-MS/MS on an orbitrap Fusion or
LUMOS for WaLP-digested samples, and on a Q-Exactive for Ub-digested samples.
MS analysis of in vitro deSUMOylation experiment. Immunoprecipitated
peptides were resuspended in 0.125% formic acid and analyzed by an Orbitrap
FusionTM LumosTM TribridTM mass spectrometer (Thermo) coupled to an EASY-
nLC 1200 (Thermo). Each sample was split and analytical replicate injections were
run to increase the number of identifications and provide metrics for analytical
reproducibility of the method. Standard peptide mix (MassPREPTM Protein
Digestion Standard Mix 1, Waters) was spiked in each sample vial in a total
quantity of 100 fmol (33 fmol per injection) prior to LC-MS/MS analysis. The
sample was loaded onto an EASY-SprayTM analytical column (PepMapTM, 75
µm× 50 cm, C18, 2 µm, 100 Å, Thermo), which was connected to an EASY-
SprayTM ionization source (Thermo). The column was heated to 45 °C for all runs.
Mobile phase solvent A was composed of 0.1% formic acid and water. Mobile
phase solvent B was composed of 0.1% formic acid, 93.5% acetonitrile, and water.
Peptides were separated using a gradient from 5% B to 32% B over 90 min and
continued to 53% B over 5 min at a constant flow rate of 300 nl min−1. Full MS
scans were obtained with a range of m/z 300–1500 at a mass resolution of 120,000
(m/z 200), with an AGC target value of 4.0E5 and maximum injection time of
50 ms. To select peptides for MSMS analysis, ions with charge states from 2 to 7
were all included, dynamic exclusion was set to 60 s with mass tolerance 10 ppm,
and intensity threshold was set at 2.0E3. Data-dependent mode was established at
top speed of 3 s. Most intense precursor ions were selected and isolated with a
window of 2m/z and fragmented by collision-induced dissociation with a nor-
malized collision energy of 35 and activation Q of 0.25. MS/MS spectra were
acquired in the ion trap at enhanced scan rate with an AGC target value of 3.0E3
and maximum injection time at 350 ms. Real-time recalibration of mass error was
performed using lock mass34 with a singly charged polysiloxane ion m/z =
371.101237.
MS/MS spectra were evaluated using SEQUEST and the Core platform from
Harvard University35–37. Files were searched against the Swissprot homo sapiens
FASTA database updated on September 2015. A mass accuracy of ±5 ppm was
used for precursor ions and 0.02 Da for product ions. Enzyme specificity was
limited to trypsin, with at least one tryptic (K- or R-containing) terminus required
per peptide and up to four mis-cleavages allowed. No enzyme specificity was
restricted for WaLP-digested samples. Cysteine carboxamidomethylation was
specified as a static modification, oxidation of methionine residues was allowed,
and digly remnant on lysine residue (+114.0429) was allowed for each enrichment
sample set. Reverse decoy databases were included for all searches to estimate false
discovery rates, and filtered using a 1% FDR in the linear discriminant module of
core. Results were further narrowed by mass accuracy based on clustering of
forward and reverse assignments in Xcorr vs. mass error plots. All quantitative
results were generated using Progenesis V4.1 (Waters Cooperation) and Skyline
Version 3.1 to extract the integrated peak area of the corresponding peptide
assignments.
Quantitative comparison of the KGG-containing peptides before and after
SENP1/2 treatment was performed using Progenesis V4.1 (Waters Cooperation)
and Skyline Version 3.1 to extract the integrated peak area of the corresponding
peptide assignments according to previously published protocols (19, 20).
Extracted ion chromatograms for peptide ions that changed in abundance between
samples were manually reviewed to ensure accurate quantitation in Skyline.
Statistical analysis of the quantitative data was done using two-tailed t-test between
SUMO proteases treated and untreated groups. The maximum negative log-p value
from three comparison pairs was used to indicate significance for abundance
changes of a certain peptide between two groups. Bar graphs of the quantitative
data were generated and clustered in Spotfire Decision Site (TIBCO Software AB)
version 9.1.2.
SILAC quantitation of Ub and SUMO. HCT116 cells were grown on DMEM
SILAC media (Thermo Scientific/Pierce) supplemented with 10% FBS, penicillin,
streptomycin, arginine (85 mg l−1), and either 13C615N2 lysine (Cambridge Isotope
Labs) or unlabeled lysine at 50 mg l−1. Cells were expanded up to twenty 15 cm
plates for heavy medium and twenty 15 cm plates in light medium to yielded 40 mg
of total protein. The cells were treated with 10 µM MG132 (Sigma) dissolved in
DMSO for 4 h or DMSO-only as the negative control. Cells were then washed with
PBS, scraped into ice-cold PBS, and counted with a TC20 cell counter (Bio-Rad).
Equal quantities of unlabeled and labeled cells from each condition were combined
and stored at −80 until lysis.
Frozen cell pellets were thawed quickly and resuspended in 4 mls of denaturing
lysis buffer containing 50 mM Tris, pH 8.2, 8 M urea, 75 mM NaCl, 1 mM Na3VO4,
1 mM β-glycerophosphate, 1 mM NaF, 2 mM NEM, 1 mM PMSF, and Roche
complete mini protease inhibitor. Cells were then sonicated on ice using 15W
power output for three cycles of 30 s with 30 s rests in between. Insoluble material
was precipitated by centrifugation at 20,000×g for 15 min at 4 °C and protein in the
supernatant was quantified by BCA assay. Typically, 5–10 mg protein was digested
for Ub identification and 10–15 mg protein was digested for SUMO identification.
For Ub identification, lys-C was added to a final concentration of 10 ng µl−1 and
incubated for 2 h at 37 °C. Then the digest was diluted to 2 M urea by addition of
50 mM Tris-HCl, pH 8.2 and trypsin (Sigma) was added to a final ratio of 1:100
and incubated at 37 °C overnight. For SUMO identification, the lysate was diluted
to 2 M urea by addition of 50 mM Tris-HCl, pH 8.2 and WaLP was added to a final
ratio of 1:100 and incubated at 37 °C overnight. Each reaction was stopped by
acidification with TFA to 1% (v/v) and clarified by centrifugation at 20,000×g for
10 min at 4 °C. Peptide solutions were then desalted using tC18 Sep-Pak (either 200
or 500 mg, Waters) as previously described38 and lyophilized.
For the SILAC experiments, initial purification of the peptides was performed
using basic pH reverse phase chromatography on a 100 mm × 10 mm ID bridged-
ethylene hybrid (BEH) C18 column with 5 µm particles (Waters) in 10 mM
ammonium formate pH 10. Using a flow rate of 3 ml min−1 and a gradient of
0–100% 10 mM ammonium formate in 90% ACN over 1 h, thirty-two fractions
were collected and every fourth fraction was pooled to obtain four fractions from
each digest. After lyophilization and resuspension in 0.5% TFA, the peptides were
desalted again with Sep-Pak tC18 cartridges (50 or 200 mg size), lyophilized, and
stored at −80 °C.
Preparation of tissue samples. Murine tissue samples such as brain, heart,
muscle, and liver were obtained from mature BALB/c mice (Cell Signaling Tech-
nology). Tissue was homogenized in 8 M urea lysis buffer (50 mM Tris pH 8.0, 8 M
urea, 1 mM vanadate, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerol-phos-
phate). Lysate was reduced by 4.5 mM DTT for 30 min at 55 °C. Reduced lysate was
alkylated with 10 mM iodoacetamide for 15 min at 25 °C in the dark. Sample was
diluted fourfold with 50 mM Tris, pH 8, and digested overnight with WaLP at
weight ratio of 1:100 at 37 °C overnight with slow rotation. Digested peptide lysate
was acidified with 20% TFA to a final concentration of 1%, and peptides were
desalted over 360-mg Sep-Pak Classic C18 columns (Waters, Milford, MA). Pep-
tides were eluted with 40% acetonitrile in 0.1% TFA and lyophilized.
nLC-MS/MS for SILAC experiments. For the SILAC samples, WaLP digest data
were collected on an Orbitrap Fusion mass spectrometer (Thermo Scientific)
equipped with a Proxeon Easy nLC 1000. Samples were resuspended in 8 µl of 5%
formic acid/5% acetonitrile and were loaded onto a 100 µm inner diameter fused-
silica micro capillary with a needle tip pulled to an internal diameter less than 5
µm. The column was packed in-house to a length of 35 cm with a C18 reverse
phase resin (GP118 resin 1.8 μm, 120 Å, Sepax Technologies). The peptides were
separated using a 120 min linear gradient from 3 to 25% buffer B (100% ACN +
0.125% formic acid) equilibrated with buffer A (3% ACN + 0.125% formic acid) at
a flow rate of 600 nL min−1. Precursor spectra were collected with a target reso-
lution of 120,000 in the Orbitrap using a scan range of 300–2000m/z. The top 10
precursors with intensity greater than 5000 were fragmented sequentially with CID
and ETD in the ion trap with the rapid scan rate, resulting in two separate spectra
for each selected precursor ion.
For SILAC samples after WaLP digestion, two searches for each file were
performed, one specifying fixed light lysine and one specifying fixed heavy lysine.
All searches allowed variable oxidation of methionine, variable protein N-terminal
methionine loss and acetylation at alanine or serine, variable peptide N-terminal
pyro-glutamate from Q, variable KGG, and fixed modification of cysteine (sample
dependent). Following the conversion of the raw data to the open format .mzXML
using Proteowizard39, peptides were identified by database search (2015 Uniprot
reviewed human proteome) with MS-GF+ trained for peptides from WaLP
digestion as described previously21. Current releases of MS-GF+ (2017-01-13) are
available at https://omics.pnl.gov/software/ms-gf with development and support at
https://github.com/sangtaekim/msgfplus. CID/ETD pairs were analyzed together
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when available from the Fusion data. The .mzid output from fixed heavy lysine
database searches was processed using R scripts40 to combine the mass of heavy
lysine and diGlycine into one modification. R scripts used in this work are available
at https://github.com/komiveslab/SUMO. All .mzid files were then converted to
pepXML for compatibility with TPP41 using idconvert.exe (Proteowizard39).
PeptideProphet was used to refine heavy and light identifications separately42.
iProphet was used to combine files corresponding to HPRP fractions from a single
condition, and to combine the results from separate heavy and light database
searches43. PTMprophet was used to generate localization scores for KGG41,44.
SUMO-remnant-containing peptides were then filtered to 1% FDR by probability
score, and ptm sites with localization scores below 0.9 were removed.
The trypsin-digested SILAC samples were analyzed on a Q-Exactive as
previously described14 and data were analyzed with the Core platform from
Harvard University36,37.
To quantify changes in SUMOylation or ubiquitylation upon MG132 treatment,
the ratio of the peak areas for the heavy vs. the light were calculated and when
protein modifications were identified by multiple peptides, the weighted average of
the ratio was computed. The log(2) of each ratio was plotted and sites with log(2)
ratios outside 1 s.d. from the median were flagged as “changing.” The proteins
containing these sites were then analyzed for GO term enrichment with metascape
(http://metascape.org/gp/index.html#/main/step1) using all human proteins as
background.
Data availability. All data, spectra, and result files are accessible via FTP at: Public
FTP link: massive.ucsd.edu/MSV000081018—Massive ID: MSV000081018. Pro-
teome exchange ID: PXD006398. The data available on the web interface reflects
the MS-GF+ output, before the 1% FDR filter was applied in TPP. The data that
support the findings of this study are also available from the corresponding author
on request.
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